Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Ketamine Showed Antidepressive Effects in Refractory Bipolar Depression

3 September 2026 · By · Wire by Fusion42

Published

3 September 2026

Topic

opportunities

◆ Sectors

Mental Health

◆ Geography

Canada

◆ Source

Read at medpagetoday.com →

◆ Verified

Fusion42 · 3 September 2026 · Fusion42 review

A randomized trial demonstrated that four ketamine infusions significantly reduced depression symptom severity compared to midazolam in outpatients with treatment-resistant bipolar I or II depression, with effects lasting up to one week and no treatment-emergent mania or psychosis observed.

This Wire brief sits within Fusion42's coverage of Mental Health.

◆ ◆ The Wire takeaway

You can position ketamine as a viable second-line treatment for patients with bipolar depression unresponsive to other therapies, backed by clinical trial data that overcomes past concerns about its safety and placebo effects.

◆ Coverage

1 source · 3 Sep 2026

◆ Related on Wire

◆ Topics

Mental Healthketaminebipolar-depressiontreatment-resistantrandomized-trialmental-health